Aletheia Research and Management

Barnes & Noble Shareholders Rubber-Stamp Poison Pill

Back in September, billionaire Ron Burkle lost his proxy war with Barnes & Noble's board, failing to kill the poison pill that kept him from upping his stake in the company. That made Wednesday's shareholders meeting all but a formality. But what's next for the nation's largest bookseller?

Is the Barnes & Noble Brawl Over Now? Probably Not

A bitter and extended proxy fight climaxed at Tuesday's shareholder meeting. In the end, B&N Chairman Riggio's defeat of dissident shareholder Burkle was more fait accompli than 11th-hour surprise. And it served far more to raise questions than provide answers.

Barnes & Noble Kicks Off Proxy Fight With Burkle

Barnes & Noble's board has sent a letter to shareholders urging them to vote to rebuff investor Ron Burkle's battle to control the bookseller. The letter is part of annual-meeting materials B&N mailed to shareholders, formally launching its proxy battle.

Ron Burkle, Barnes & Noble Hit a Snag

Barnes & Noble and its second-largest shareholder, billionaire Ron Burkle, appears to be over. The two camps have reached a settlement that would give Burkle three board seats in exchange for dropping his lawsuit against the bookseller.

Barnes & Noble Denies Ron Burkle More Stock

Ron Burkle is once again a stockholder scorned, his latest attempt to get a better foothold in Barnes & Noble's stock denied. The book retailer's board responded that "there is absolutely no basis whatsoever for the allegations made."

An Antidote to Barnes & Nobles' Poison Pill?

When billionaire Ron Burkle went on a Barnes & Noble stock buying spree late last year, the bookseller responded with a "poison pill" measure to prevent a hostile takeover. But another firm's stock buys suggest there's an alliance in the works that may hold the antidote to the poison.